Award
NIH Reporter #3R01DA059234-03S1
Hemp-derived Cannabidiol for the treatment of cannabis use disorder in concentrate users: A double-blind placebo-controlled randomized trial
Recipient
University of Colorado, Boulder, CO, United States
Award Amount
$98,952.00
Ceiling
$98,952.00
Awarded
July 10, 2025
Identifier
3R01DA059234-03S1
This NIH-funded research project investigates the efficacy of hemp-derived cannabidiol (CBD), with and without THC, in treating cannabis use disorder among concentrate users through a double-blind placebo-controlled randomized trial.
Description
A placebo-controlled randomized trial comparing the effects of hemp-derived CBD with and without THC, relative to placebo, on reducing cannabis use and Cannabis Use Disorder (CUD) symptoms in adult treatment seeking cannabis concentrate users with CUD. The study aims to evaluate the effectiveness of hemp-derived CBD products, which are widely available, in reducing cannabis use and related symptoms.